Azitra reports Phase 1b safety data for ATR12-351 in Netherton syndrome; no severe adverse events, 50% enrolled

Azitra, Inc.

• No severe or serious adverse events in ongoing Phase 1b trial of ATR12-351; application site reactions transient, self-resolving, observed bilaterally.
• Trial 50% enrolled; six patients dosed with ATR12-351 (engineered S. epidermidis strain delivering LEKTI protein).
• Drug candidate generally safe and well-tolerated with occasional mild to moderate local symptoms (itch, redness, burning).
• Azitra presenting at 2025 BIO International Convention on June 17, 2025 (12:00PM ET in Boston).